As per the terms of the agreement, Nycomed is expected to take up the responsibility of marketing and distributing Zenpep (pancrelipase) delayed-Release capsules in Russia and CIS, as well as Georgia and Mongolia, subject to regulatory review and approval of the product in those territories.
Zenpep is a pancreatic enzyme agent which is used as a digestive aid in patients with cystic fibrosis and other conditions that impair the proper digestion of food.
Eurand Commercial Operations vice president Andrew Thompson said that this agreement represents an important development in the international marketing strategy for Zenpep.
Nycomed Group senior vice president Nycomed Russia-CIS president Jostein Davidson said they believe ZENPEP, which has been specifically formulated to meet the FDA’s stringent guidelines for PEPs, will offer physicians an important new treatment option for their patients with pancreatic insufficiency.